# Atrial Fibrillation Management in Older Adults

## Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, with prevalence increasing exponentially with age: approximately 1 percent at age 60, 5 percent at age 70, 10 percent at age 80, and 15 to 20 percent in adults aged 85 and older. AF currently affects approximately 6 million Americans, a number projected to reach 12 million by 2050 as the population ages. The clinical significance of AF extends far beyond its hemodynamic consequences: AF independently increases stroke risk five-fold, and AF-related strokes are characteristically larger, more disabling, and more frequently fatal than strokes from other etiologies. In elderly patients, AF is additionally associated with heart failure, cognitive decline, dementia, falls, reduced quality of life, and increased all-cause mortality. The management of AF in the elderly requires careful balancing of the substantial benefits of stroke prevention against the risks of bleeding, a calculus that nearly always favors anticoagulation.

## Pathophysiology in the Elderly

The pathophysiology of AF in elderly patients reflects the convergence of age-related atrial remodeling and accumulated comorbid disease. Chronic hypertension, valvular disease, and heart failure produce atrial fibrosis and dilation, creating the substrate for AF maintenance. Ectopic foci in the pulmonary veins serve as triggers that initiate AF episodes, while the fibrotic atrial substrate perpetuates the arrhythmia. Age-related changes include increased interstitial fibrosis, chronic low-grade inflammation, oxidative stress, and shortening of the atrial effective refractory period, all of which lower the threshold for AF initiation and maintenance. Autonomic imbalance, with increased vagal and sympathetic triggers, further contributes. The most common comorbidities associated with AF in the elderly include hypertension (present in 70 percent), heart failure (30 to 40 percent), coronary artery disease (20 to 30 percent), diabetes (20 percent), obesity, sleep apnea, and thyroid disease.

## Classification

AF is classified based on temporal pattern. Paroxysmal AF terminates spontaneously or with intervention within 7 days. Persistent AF is sustained beyond 7 days and requires cardioversion for termination. Long-standing persistent AF has been present for more than 12 months. Permanent AF has been accepted by both physician and patient, with no further rhythm control attempted. In elderly patients, AF frequently progresses from paroxysmal to persistent and ultimately to permanent forms over time.

## Diagnosis

The electrocardiographic hallmarks of AF are an irregularly irregular rhythm, absence of organized P waves, and variable R-R intervals. Ambulatory monitoring extends detection beyond the standard ECG: Holter monitors provide 24 to 48 hours of continuous recording, event recorders monitor for 2 to 4 weeks, and implantable loop recorders provide years of monitoring capability. Wearable consumer devices including the Apple Watch and Fitbit are increasingly detecting AF, though single-lead ECG confirmation is required before initiating treatment. The APPLE Heart Study found that smartwatch-detected irregular pulse was confirmed as AF in 34 percent of cases on follow-up. Screening for AF in elderly populations has demonstrated value: the SAFE trial showed that systematic screening in primary care using pulse palpation followed by ECG detected 1.6 percent new AF in adults aged 65 and older.

## Stroke Risk Assessment — CHA2DS2-VASc

### Score Components

The CHA2DS2-VASc score quantifies stroke risk in non-valvular AF using the following components: congestive heart failure (1 point), hypertension (1 point), age 75 or older (2 points), diabetes mellitus (1 point), prior stroke, transient ischemic attack, or thromboembolism (2 points), vascular disease including myocardial infarction, peripheral arterial disease, or aortic plaque (1 point), age 65 to 74 (1 point), and female sex category (1 point).

### Implications for Elderly

The scoring system has profound implications for elderly patients: all patients aged 75 and older automatically score at least 2 points from age alone, meaning that virtually all elderly patients with AF meet the threshold for anticoagulation. Annual stroke risk escalates with score: approximately 2.2 percent at a score of 2, 4.0 percent at a score of 4, and 9.8 percent at a score of 6. The 2023 AHA/ACC/HRS guidelines provide a Class I recommendation for oral anticoagulation when CHA2DS2-VASc is 2 or greater in men or 3 or greater in women.

## Bleeding Risk Assessment — HAS-BLED

The HAS-BLED score assesses bleeding risk using the following components: hypertension with uncontrolled systolic blood pressure above 160 mmHg (1 point), abnormal renal or liver function (1 to 2 points), prior stroke (1 point), bleeding history or predisposition (1 point), labile INR when on warfarin (1 point), elderly age above 65 (1 point), and concomitant drugs (antiplatelets or NSAIDs) or alcohol use (1 to 2 points). A score of 3 or above indicates increased bleeding risk, but this is not a contraindication to anticoagulation. Rather, it identifies modifiable risk factors that should be addressed while continuing to anticoagulate. The key principle is that high bleeding risk and high stroke risk often coexist in the same patient, and the stroke risk almost always outweighs the bleeding risk when both are elevated.

<image>A risk-benefit decision framework for anticoagulation in elderly AF patients. Show a balance scale diagram. On the left side (stroke risk), stack CHA₂DS₂-VASc score components relevant to elderly — show that age ≥75 alone gives 2 points, and typical elderly patients score 3-6. Include annual stroke rates for each score level. On the right side (bleeding risk), show HAS-BLED components. Below the scale, show a decision pathway: CHA₂DS₂-VASc ≥2 men / ≥3 women → anticoagulate (DOAC preferred). Include a table comparing DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) with doses, renal adjustments, and key trial results in elderly subgroups. Highlight apixaban 5mg BID as generally preferred in elderly due to ARISTOTLE data (lowest bleeding rates). Include a prominent box stating: "HIGH BLEEDING RISK IS NOT A CONTRAINDICATION TO ANTICOAGULATION — it is a signal to address modifiable bleeding risk factors while still anticoagulating." Show modifiable bleeding risk factors to address (BP control, stop NSAIDs, limit alcohol, stabilize INR if on warfarin).</image>

## Anticoagulation

| DOAC | Standard Dose | Reduced Dose | Dose Reduction Criteria | Key Trial | Renal Clearance | Elderly Advantage/Concern |
|------|-------------|-------------|------------------------|-----------|----------------|--------------------------|
| Apixaban | 5 mg BID | 2.5 mg BID | ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5 | ARISTOTLE | 27% | Best bleeding safety; generally preferred |
| Rivaroxaban | 20 mg daily with food | 15 mg daily | CrCl 15–50 | ROCKET AF | 36% | Once-daily dosing; higher GI bleeding |
| Edoxaban | 60 mg daily | 30 mg daily | CrCl 15–50, weight ≤60 kg, or strong P-gp inhibitor | ENGAGE AF | 50% | Avoid if CrCl >95 (paradoxical) |
| Dabigatran | 150 mg BID | 75 mg BID | CrCl 15–30 | RE-LY | 80% | Specific reversal agent (idarucizumab); avoid in significant CKD |

### Direct Oral Anticoagulants (DOACs) — Preferred Over Warfarin in Elderly

Apixaban (Eliquis) is dosed at 5 mg twice daily, with a reduced dose of 2.5 mg twice daily when at least two of the following criteria are met: age 80 or older, weight 60 kg or below, or serum creatinine 1.5 mg/dL or above. The ARISTOTLE trial demonstrated that apixaban was superior to warfarin for stroke prevention (21 percent reduction), with significantly less major bleeding (31 percent reduction) and less intracranial hemorrhage (58 percent reduction). Apixaban has the best safety profile among the DOACs in elderly patients and is generally the preferred agent. It should be avoided when creatinine clearance is below 15 mL/min (US label) or below 25 mL/min (European guidance).

Rivaroxaban (Xarelto) is dosed at 20 mg daily with food, reduced to 15 mg daily when creatinine clearance is 15 to 50 mL/min. The ROCKET AF trial demonstrated non-inferiority to warfarin for stroke prevention with similar major bleeding and less intracranial hemorrhage. Once-daily dosing provides an adherence advantage, though higher gastrointestinal bleeding rates compared to warfarin are a concern in elderly patients.

Edoxaban (Savaysa) is dosed at 60 mg daily, reduced to 30 mg if creatinine clearance is 15 to 50 mL/min, weight is 60 kg or below, or a concomitant strong P-glycoprotein inhibitor is used. The ENGAGE AF-TIMI 48 trial showed non-inferiority with less major bleeding. A paradoxical caveat applies: edoxaban should not be used when creatinine clearance exceeds 95 mL/min due to increased ischemic stroke risk.

Dabigatran (Pradaxa) is dosed at 150 mg twice daily, with 75 mg twice daily when creatinine clearance is 15 to 30 mL/min. The RE-LY trial showed the 150 mg dose was superior to warfarin for stroke prevention, though higher gastrointestinal bleeding in elderly patients is a concern. Dabigatran is uniquely reversible with idarucizumab (Praxbind), a specific reversal agent. As the DOAC most dependent on renal clearance (80 percent), it should be avoided in significant chronic kidney disease.

### Warfarin

Warfarin remains indicated for patients with mechanical heart valves, severe mitral stenosis, patient preference, or severe CKD with creatinine clearance below 15 mL/min. The target INR is 2.0 to 3.0, with time in therapeutic range (TTR) above 70 percent necessary for optimal outcomes. Elderly patients present particular challenges with warfarin including increased sensitivity (requiring lower doses), numerous drug and food interactions, frequent monitoring requirements, and fall risk. The SAMe-TT2R2 score predicts poor TTR, and patients likely to achieve poor TTR should preferentially receive a DOAC.

### Special Considerations

#### Frailty and Anticoagulation

Frailty is not a contraindication to anticoagulation. In fact, frail elderly patients have higher stroke risk and therefore derive greater absolute benefit from anticoagulation. The FRAIL-AF trial demonstrated the feasibility of DOAC use in frail elderly patients with acceptable bleeding rates. Apixaban is preferred in frail patients due to its best bleeding safety profile.

#### Falls Risk and Anticoagulation

Falls risk is the most common inappropriate reason cited for withholding anticoagulation. The seminal calculation by Man-Son-Hing and colleagues demonstrated that a patient would need to fall approximately 295 times per year for the bleeding risk of anticoagulation to exceed the stroke prevention benefit. The appropriate approach is to address fall risk factors and anticoagulate simultaneously, not to choose one over the other.

#### Dementia and Anticoagulation

AF independently increases dementia risk with a hazard ratio of 1.4, and anticoagulation may reduce dementia incidence. Cognitive impairment creates practical challenges regarding medication adherence and INR monitoring compliance. Solutions include using DOACs (which require no monitoring), pill organizers, caregiver involvement, and pharmacy blister packs. Dementia alone is not a contraindication to anticoagulation.

#### Left Atrial Appendage Occlusion (LAAO)

The Watchman device, studied in the PROTECT AF and PREVAIL trials, demonstrated non-inferiority to warfarin for stroke prevention. LAAO is indicated when long-term anticoagulation is truly contraindicated, such as in cases of recurrent life-threatening bleeding, but not simply for falls risk. The procedure requires short-term anticoagulation or antiplatelet therapy post-implantation (45 days of dual antiplatelet therapy, then single antiplatelet for 6 months).

## Rate vs. Rhythm Control

### Rate Control

Rate control is generally the preferred strategy in elderly patients, particularly those with permanent AF and minimal symptoms. The AFFIRM trial demonstrated no mortality benefit of rhythm control over rate control, with a trend toward increased mortality with rhythm control attributable to antiarrhythmic drug toxicity. The RACE II trial established that lenient rate control targeting a resting heart rate below 110 bpm is non-inferior to strict control targeting below 80 bpm for composite cardiovascular outcomes.

First-line rate control agents include beta-blockers (metoprolol 25 to 200 mg daily) and non-dihydropyridine calcium channel blockers (diltiazem 120 to 360 mg daily), with the caveat that calcium channel blockers should be avoided in HFrEF and beta-blockers preferred in that setting. Second-line therapy includes digoxin at 0.0625 to 0.125 mg daily with a target level of 0.5 to 0.8 ng/mL, useful as an add-on agent with close monitoring in renal impairment. Amiodarone serves as third-line rate control due to significant toxicity concerns. AV node ablation with permanent pacemaker implantation is reserved for patients with refractory symptoms and rapid ventricular rate despite medications.

### Rhythm Control

The EAST-AFNET 4 trial in 2020 demonstrated that early rhythm control, initiated within one year of AF diagnosis, reduced cardiovascular events compared to rate control, potentially shifting the paradigm toward earlier rhythm control. However, the mean age in the trial was 70, and benefits were primarily from antiarrhythmic drugs and ablation. Rhythm control should be considered when patients are highly symptomatic, have HFrEF where maintaining sinus rhythm may improve ejection fraction, or when tachycardia-mediated cardiomyopathy is suspected.

Antiarrhythmic drug options in elderly patients are limited. Flecainide and propafenone should be avoided in structural heart disease, limiting their use in elderly patients, the majority of whom have structural disease. Sotalol, a combined beta-blocker and class III antiarrhythmic, requires QTc monitoring and renal dosing and carries proarrhythmic risk. Amiodarone is the most effective agent for maintaining sinus rhythm but has an extensive toxicity profile including thyroid dysfunction (hypothyroidism 5 to 22 percent, hyperthyroidism 3 to 10 percent), pulmonary toxicity (1 to 5 percent), hepatotoxicity, neuropathy, photosensitivity, and corneal deposits. When used, the lowest effective dose of 100 to 200 mg daily for maintenance should be employed, with monitoring of TSH every 6 months, pulmonary function tests annually, liver function tests every 6 months, and ophthalmologic examination annually. Dronedarone (Multaq) is less toxic than amiodarone but must be avoided in heart failure (the ANDROMEDA trial showed increased mortality) and in permanent AF (the PALLAS trial showed increased events). Catheter ablation with pulmonary vein isolation is effective in elderly patients though complication rates are higher; it should be considered in drug-refractory symptomatic AF, and the CASTLE-AF trial demonstrated particular benefit in patients with HFrEF.

## Geriatric-Specific Issues

### AF and Cognitive Decline

AF is independently associated with cognitive decline and dementia even in the absence of clinical stroke. Proposed mechanisms include silent cerebral infarcts (found in 20 to 40 percent of AF patients), chronic cerebral hypoperfusion during AF episodes, and systemic inflammation. Observational data suggest that anticoagulation may slow cognitive decline and reduce dementia incidence compared to no treatment, potentially providing neuroprotective benefits beyond stroke prevention.

### Anticoagulation Management Around Procedures

For procedures with low bleeding risk (dental procedures, cataract surgery, minor dermatologic procedures), DOACs can be continued. For moderate- to high-bleeding-risk procedures, DOACs should be held for 1 to 2 days before surgery: apixaban and rivaroxaban require 48 hours of cessation, while dabigatran requires 48 to 72 hours if creatinine clearance is 50 to 80 mL/min and 96 hours if creatinine clearance is 30 to 50 mL/min. Bridging anticoagulation is generally not needed for DOACs, as the BRIDGE trial demonstrated that no bridging was non-inferior to bridging with warfarin. DOACs should be resumed 24 to 72 hours postprocedure depending on the bleeding risk and adequacy of hemostasis.

<image>A comprehensive AF management algorithm for elderly patients. Start with "AF diagnosed in patient ≥65." First branch: "Assess stroke risk (CHA₂DS₂-VASc) and bleeding risk (HAS-BLED)." Show that virtually all elderly patients qualify for anticoagulation. DOAC selection decision tree: Standard dosing vs. dose-reduced (show specific criteria for each DOAC). Second branch: "Symptom assessment and rate vs. rhythm control decision." Rate control pathway: beta-blocker or CCB → target HR <110 → add digoxin if needed → AV node ablation + pacemaker if refractory. Rhythm control pathway (consider if early AF <1 year, symptomatic, or HFrEF): cardioversion → antiarrhythmic drug (amiodarone most common in elderly) or catheter ablation. Include geriatric-specific boxes throughout: "Frailty does NOT contraindicate anticoagulation," "Falls risk does NOT contraindicate anticoagulation," "Always address modifiable bleeding risk factors," "Monitor for cognitive decline." Show comorbidity management at the bottom: BP control, HF management, sleep apnea screening, thyroid function, weight management, alcohol reduction.</image>

## Key Clinical Pearls

- Virtually all elderly patients with AF qualify for anticoagulation (CHA₂DS₂-VASc ≥2 from age alone) — the decision is usually not WHETHER to anticoagulate but WHICH agent to use
- Apixaban is generally the preferred DOAC in elderly due to the best bleeding safety profile (ARISTOTLE) — use reduced dose (2.5 mg BID) only when ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5
- Falls risk and frailty are NOT contraindications to anticoagulation — a patient would need to fall 295 times/year for the bleeding risk to exceed the stroke benefit
- HAS-BLED ≥3 does not mean "do not anticoagulate" — it means "address modifiable bleeding risk factors while anticoagulating"
- Rate control with a lenient target (HR <110 at rest) is as effective as strict control (RACE II) and avoids over-medication in elderly
- EAST-AFNET 4 suggests early rhythm control may improve outcomes — but this applies to newly diagnosed AF, not long-standing permanent AF
- AF independently increases dementia risk — anticoagulation may be neuroprotective beyond stroke prevention

## References
1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation. *Circulation*. 2024;149(1):e1-e156.
2. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). *N Engl J Med*. 2011;365(11):981-992.
3. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4). *N Engl J Med*. 2020;383(14):1305-1316.
4. Van Gelder IC, Groenveld HF, Crijns HJGM, et al. Lenient versus strict rate control in patients with atrial fibrillation (RACE II). *N Engl J Med*. 2010;362(15):1363-1373.
5. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. *Arch Intern Med*. 1999;159(7):677-685.